Depending on the presence of NRAS- or c-KIT-mutations, either MEKi, c-KIT inhibitors, immunotherapy with anti-PD-1 checkpoint blockers, or polychemotherapy are recommended for the treatment of advanced non-BRAFV600mut melanoma [12]. Here, KIT is linked to melanoma.